Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review

• Published in: Kidney medicine Vol. 3; no. 6; pp. 1065 - 1073
• Main Authors: Daza-Arnedo, Rodrigo, Rico-Fontalvo, Jorge-Eduardo, Pájaro-Galvis, Nehomar, Leal-Martínez, Víctor, Abuabara-Franco, Emilio, Raad-Sarabia, María, Montejo-Hernández, Juan, Cardona-Blanco, María, Cabrales-Juan, José, Uparella-Gulfo, Isabella, Montiel, Luis Salgado
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-11-2021; Elsevier
• Subjects: diabetes mellitus; Diabetic kidney disease; diabetic nephropathy; dipeptidyl peptidase-4; DPP-4 inhibitors; incretin system; Review; diabetes mellitus; DPP-4 inhibitors; incretin system; diabetic nephropathy; dipeptidyl peptidase-4; Diabetic kidney disease
• ISSN: 2590-0595; 2590-0595
• DOI: 10.1016/j.xkme.2021.07.007

Diabetic kidney disease is one of the most frequent complications in patients with diabetes mellitus and affects morbidity and mortality. The recent therapies include oral hypoglycemic drugs that, in addition to optimizing glycemic control and reducing the risk of hypoglycemia, may affect the development and progression of diabetic kidney disease; these novel therapies include inhibitors of the enzyme dipeptidyl peptidase 4 (DPP-4), a group of oral hypoglycemic therapeutic agents that act at the level of the incretin system. DPP-4 inhibitors show additional pleiotropic effects in in vitro models, reducing inflammation, fibrosis, and oxidative damage, further suggesting potential kidney protective effects. Although existing trials suggest a possible benefit in the progression of diabetic kidney disease, further studies are needed to demonstrate kidney-specific benefits of DPP-4 inhibitors.